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Abstract  Pancreatic  cancer  is  one  of  the  digestive  cancers  with  the  poorest  prognosis,  so  an
early and  correct  diagnosis  is  of  utmost  importance.  With  the  development  of  new  therapeutic
options an  accurate  staging  is  essential.  Endoscopic  ultrasonography  (EUS)  has  a  major  role  in
all stages  of  the  management  of  these  patients.
EUS  has  a  high  accuracy  in  the  diagnosis  of  pancreatic  adenocarcinoma  and  the  possibility  to
perform ﬁne-needle  aspiration/biopsy  (FNA/FNB)  increases  the  diagnostic  yield  of  EUS.  There  is
still no  consensus  on  the  several  technical  aspects  of  FNA,  namely  on  the  rapid  on-site  evaluation
(ROSE), the  diameter  and  type  of  needle,  the  number  of  passes  and  the  use  of  stylet  and  suction.
Contrast-enhanced  EUS  (CE-EUS)  and  EUS  elastography  (EUS-E)  have  been  used  in  recent  years
as an  adjunct  to  EUS-FNA.  Given  the  higher  sensitivity  of  these  techniques  a  negative  cytology  by
EUS-FNA should  not  exclude  malignancy  when  CE-EUS  and/or  EUS-E  are  suggestive  of  pancreatic
neoplasia.  EUS  remains  one  of  the  main  methods  in  the  staging  of  pancreatic  adenocarcinoma,
namely to  further  evaluate  patients  with  non-metastatic  disease  that  appears  resectable  on
initial imaging.
EUS  is  crucial  for  an  accurate  preoperative  evaluation  of  pancreatic  cancer  which  is  essential
to choose  the  correct  management  strategy.  The  possibility  to  obtain  samples  from  suspicious
lesions or  lymph  nodes,  by  means  of  EUS-guided  ﬁne-needle  aspiration  as  well  as  the  use  of
contrast-enhanced  and  elastography,  makes  EUS  an  ideal  modality  for  the  diagnosis  and  staging
of pancreatic  cancer.
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opc¸ões  terapêuticas  é  essencial  um  estadiamento  preciso.  A  ecoendoscopia  apresenta  um  papel
relevante  em  todas  as  fases  da  abordagem  destes  doentes.
A acuidade  da  ecoendoscopia  no  diagnóstico  de  adenocarcinoma  pancreático  é  elevada.
A possibilidade  de  realizac¸ão  de  punc¸ão  aspirativa  aumenta  o  potencial  diagnóstico,  não
havendo  ainda  consenso  relativamente  a  vários  aspetos  da  técnica,  nomeadamente  em  relac¸ão
à presenc¸a  de  citopatologista  durante  o  procedimento,  tipo  e  diâmetro  de  agulha,  número  de
passagens  e  utilizac¸ão  estilete  e  aspirac¸ão.  Nos  anos  recentes  tem-se  assistido  à  utilizac¸ão  de
ecoendoscopia  com  contraste  (CE-EUS)  ou  elastograﬁa  (EUS-E)  como  adjuvante  da  ecoendo-
scopia.  Estas  técnicas  apresentam  elevada  sensibilidade  e  uma  citologia  negativa  não  exclui
malignidade  se  a  CE-EUS  e/ou  EUS-E  apresentarem  características  sugestivas  de  malignidade.
A ecoendoscopia  mantém-se  um  dos  principais  métodos  no  estadiamento  do  adenocarcinoma
pancreático,  em  especial  na  presenc¸a  de  doenc¸a  não  metastática  que  aparenta  ser  ressecável
noutras técnicas  imagiológicas.
A ecoendoscopia  é  fundamental  na  avaliac¸ão  pré-operatória  do  adenocarcinoma  pancreático
e na  deﬁnic¸ão  da  correta  estratégia  de  tratamento.  A  possibilidade  de  obtenc¸ão  de  amostras
de lesões  ou  adenopatias  suspeitas,  através  de  punc¸ão  aspirativa,  assim  como  a  utilizac¸ão  de
contraste e  elastograﬁa,  fazem  da  ecoendoscopia  uma  técnica  ideal  no  diagnóstico  e  estadia-
mento.
© 2015  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.U.
Este é  um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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g. Introduction
ancreatic  neoplasia,  particularly  exocrine  pancreatic  can-
er,  is  a  common  cause  of  cancer-related  death  and  is
econd  only  to  colorectal  cancer  as  a  cause  of  digestive
ancer-related  death.1 Due  to  its  aggressive  behavior  and
ate  presentation,  this  disease  has  a  poor  prognosis  with  a
ery  low  ﬁve-year  survival  rate.  Surgical  resection  offers
he  only  potential  cure,  but  only  10--15%  of  patients  are
andidates  for  pancreatectomy.  Because  of  these  reasons
t  is  of  utmost  importance  to  do  an  early  and  correct  diag-
osis  as  well  as  the  most  precise  staging  before  providing
herapeutic  options.
This  paper  will  discuss  the  role  of  endoscopic  ultrasound
n  the  diagnosis  and  staging  of  pancreatic  cancer.
. How good is EUS guided FNA in the
iagnosis of solid pancreatic lesions?
US-FNA  is  technically  successful  in  90--95%  of  procedures,
ith  high  sensitivity  and  speciﬁcity  for  malignancy.  This  is
onﬁrmed  by  a  recent  meta-analysis  that  showed  sensitivity
f  85%  and  speciﬁcity  of  98%.2 When  patients  with  atypi-
al  or  suspicious  cytology  were  reclassiﬁed  as  positive  for
alignancy,  the  sensitivity  increased  to  91%,  with  a slight
ecrease  in  speciﬁcity.  The  negative  predictive  value  of  64%
eﬂects  the  important  fact,  that  a  negative  result  of  EUS-
NA  does  not  exclude  malignancy  with  absolute  certainty.
In  spite  of  this  excellent  accuracy,  there  is  some  discus-
ion  if  all  pancreatic  lesions  should  be  sampled,  particularly
n  patients  who  are  good  surgical  candidates  with  lesions
hat  appear  resectable.  This  is  mainly  due  to  the  fact  that
US-FNA  can  be  hampered  by  the  presence  of  stenosis  or
(
i
ather  anatomical  factors;  its  accuracy  appears  to  be  dimin-
shed  in  the  background  of  chronic  pancreatitis3 and  there
s  some  concern  with  needle  tract  seeding,  even  if  this  last
spect  has  only  been  anecdotally  reported.4 On  the  other
and,  performing  EUS-FNA  to  all  patients  may  be  advanta-
eous  since  it  allows  ruling  out  other  types  of  malignancy,5
ssists  with  surgical  planning  and  conﬁrms  the  diagnosis  in
atients  who  want  veriﬁcation  prior  to  surgery.
. ROSE, needle, suction and passes
everal  methodological  features  can  contribute  to  the  suc-
ess  of  EUS  guided  FNA/FNB.  These  include  the  rapid  on-site
valuation  (ROSE),  the  type  of  needle,  the  number  of  passes
nd  the  use  of  stylet  and  suction.
The  role  of  ROSE  and  its  relevance  in  EUS-FNA  has  been
escribed  in  a  guideline  published  by  the  European  Society
f  Gastrointestinal  Endoscopy.4 Its  use  is  considered  contro-
ersial  even  if  a  recent  meta-analysis6 and  various  studies
ave  shown  an  improvement  in  adequacy  rate.7,8 This  is
ainly  due  to  the  fact  that  ROSE  only  seems  to  improve  the
dequacy  rate  when  it  is  below  90%  and  many  recent  stud-
es  have  reported  adequacy  rates  superior  to  90%  without
he  use  of  ROSE,  indicating  that,  in  high-volume  centers,
OSE  may  not  be  indispensable.  A  valid  alternative  to  the
resence  of  a  cytopathologist  is  the  preparation  of  slides
y  a  cytotechnician.  This  was  retrospectively  evaluated  by
lsohaibani  et  al  and  the  ﬁnal  diagnosis  was  higher  in  the
roup  with  on-site  cytotechnologists  preparing  the  slides
77%  vs.  53%)  and  providing  initial  consideration  about  spec-
men  adequacy.8
Unfortunately  not  all  EUS-FNA  performing  units  have
ccess  to  ROSE.  In  such  cases  it  is  of  utmost  importance
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rEndoscopic  ultrasound  in  the  diagnosis  of  pancreatic  cancer
to  optimize  the  FNA  technique,  namely  the  type  of  needle
and  the  number  of  passes.  The  two  most  common  needles
used  to  obtain  cytology  specimens  are  the  22-  and  25-gauge
needles.  Several  studies,  including  4  randomized  controlled
trials,  have  compared  their  cytological  yield  in  the  diagnosis
of  pancreatic  malignancy.9--12 In  general,  these  studies  have
not  found  signiﬁcant  differences  between  both  needles,  but
suggest  that  25  gauge  could  perform  better  in  exceedingly
ﬁbrotic  lesions  and  those  located  in  the  head  or  uncinate
process.  In  a  recent  meta-analysis,  that  included  8  studies
with  1292  patients,  the  sensitivity  of  the  25-gauge  needle
was  higher  than  the  22-gauge  needle  (93%  vs.  85%)  with
similar  speciﬁcity.13
Previous  studies,  using  the  22-gauge  needle,  showed  that
sensitivity  improved  with  an  increase  in  the  number  of
passes.14 So,  it  was  suggested  that  in  absence  of  ROSE  at
least  7  passes  should  be  performed  in  pancreatic  lesions.
However  recent  advances  in  the  EUS-FNA  technique  and  the
later  development  of  the  25-gauge  needle  should  probably
lead  to  a  re-evaluation  of  this  recommendation.  In  fact,
a  recent  prospective  study  using  the  25-gauge  needle  sug-
gested  that  4  passes  may  be  sufﬁcient  to  provide  adequate
cellularity  in  the  absence  of  ROSE.15
It  was  previously  believed  that  the  use  of  a  stylet  during
EUS-FNA  prevents  clogging  of  the  needle  lumen  by  GI  wall
tissue,  which  could  limit  the  ability  to  aspirate  cells  from  the
target  lesion.  Hence,  the  use  of  the  stylet  is  routine  practice
for  some  endosonographers,  even  though  its  insertion  and
removal  is  cumbersome  and  time  consuming.  Several  stud-
ies,  including  3  randomized  controlled  trials  have  addressed
this  subject.16--18 In  none  of  these  studies  the  use  of  stylet
was  associated  with  better  specimen  adequacy  or  improved
diagnostic  yield  for  malignancy.  In  the  study  by  Sahai  et  al
there  was  inclusive  a  better  quality  of  the  specimen  and
diminished  bloodiness  without  the  stylet.16 The  stylet  can
also  be  used  to  express  the  aspirate  and  this  was  evaluated  in
a  recent  randomized  controlled  trial.  There  were  no  differ-
ences  between  reinsertion  of  the  stylet  or  air  ﬂushing  with
regard  to  the  number  of  diagnostic  samples,  overall  accu-
racy,  cellularity  and  air-drying  artifact.19 Altogether,  these
data  does  not  support  the  use  of  a  stylet  during  EUS-FNA.
A  more  controversial  topic  is  the  use  of  suction  dur-
ing  EUS-FNA  since  quality  data  from  appropriate  trials  are
scarce.  A  randomized  controlled  trial  by  Lee  et  al19 that
focused  on  81  patients  with  solid  pancreatic  lesions  revealed
a  higher  accuracy  in  the  group  where  suction  was  used
(85.2%  vs.  75.9%)  despite  the  increased  bloodiness.  This
trial  used  both  the  22-  and  25-gauge  needle  which  can  be  a
confounding  factor.  The  theoretical  advantage  of  suction  in
pancreatic  lesions  is  to  improve  sample  cellularity  since  pan-
creatic  adenocarcinoma  tends  to  be  a  ﬁbrotic  not  densely
cellular  lesion.
In certain  pancreatic  lesions,  such  as  lymphoma,  neu-
roendocrine  tumors  (NET)  or  autoimmune  pancreatitis,  it
might  be  helpful  to  perform  a  histological  analysis.  The
techniques  and  methods  to  do  so  are  beyond  the  scope  of
this  paper  and  those  interested  are  referred  to  an  excellent
review  by  Panic  et  al.20 In  a  hand  stroke,  adequate  histologic
samples  can  be  obtained  using  19-  and  22-gauge  ProCore  or
regular  needles.  On  the  other  hand,  the  use  of  the  EUS-
Trucut  needle  has  been  hampered  by  technical  difﬁculties
and  low  yield  in  the  transduodenal  route.  Also,  the  25-gauge
t
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eedle  does  not  seem  to  be  adequate  to  collect  core  sample
nd  the  same  applies  to  the  more  recent  25-gauge  ProCore
eedle,  as  shown  by  a  recent  study  in  which  a  histologic  core
as  found  in  only  32%  of  50  patients  with  solid  pancreatic
esions.21 Interestingly,  combining  histologic  and  cytological
nalysis  may  improve  overall  sensitivity.22
In  summary,  if  one  feels  the  need  to  improve  the  results  of
US-FNA  in  solid  pancreatic  lesions,  the  ﬁrst  attitude  should
robably  be  to  contact  the  pathology  department  in  order
o  arrange  an  in-room  cytopathologist  or  technician.  If  that
s  not  possible,  a  25-gauge  needle  should  be  used,  doing  at
east  4  passes  with  suction.  The  acquisition  of  a fragment  for
istological  analysis  should  be  considered,  whether  using  a
edicated  FNB  needle  or  a  conventional  one.  Lastly,  if  EUS-
NA  fails,  repeating  the  procedure  should  be  considered,
ince  it  has  been  demonstrated  that  this  will  improve  the
iagnostic  rate.
.  Contrast-enhanced EUS and
US-elastography
US  provides  high-resolution  images  of  the  pancreas  and
t  is  considered  one  of  the  most  accurate  methods  for  the
iagnosis  and  staging  of  pancreatic  neoplasia.23,24 Even  with
he  addition  of  tissue  sampling  via  FNA,  some  limitations
xist  in  the  differentiation  of  benign  from  malignant  solid
ancreatic  lesions.  EUS--FNA  may  be  technically  demanding
nd  multiple  punctures  may  be  needed  to  obtain  ade-
uate  cytological  samples,  which  may  be  associated  with
ew  but  not  insigniﬁcant  complications  such  as  acute  iatro-
enic  pancreatitis,  bleeding,  and  infection.25,26 In  addition,
US-FNA  provides  false-negative  results  up  to  20--40%  for
alignancy,  especially  in  patients  with  underlying  chronic
ancreatitis.2,27 Recent  innovations  in  EUS  that  intended
o  address  these  limitations  include  contrast-enhanced  EUS
CE-EUS)  and  EUS  elastography  (EUS-E).28--31
.1.  Contrast-enhanced  EUS  (CE-EUS)
E-EUS  allows  real-time  evaluation  of  the  microvasculature
f  the  lesion  and  the  surrounding  parenchyma  through  the
se  of  an  intravenous  ultrasound  contrast  agent  (UCA)31--33
Fig.  1).  Second-generation  UCAs,  such  as  Sonovue  and  Son-
zoid,  are  composed  of  a  microsphere  containing  an  inert
as.32 Compared  with  ﬁrst-generation  UCAs  they  have  higher
tability  allowing  real-time  vascular  images  for  a  prolonged
ime.32 CE-EUS  can  be  performed  by  using  color  or  power
oppler  as  a  generic  signal  intensiﬁer  or,  more  appropriately,
y  using  a  dedicated  contrast  harmonic-enhanced  EUS.34
The  evaluation  of  CE-EUS  images  can  be  done  qualita-
ively  or  quantitatively.  In  qualitative  CE-EUS  the  enhance-
ent  of  the  lesion  is  compared  with  that  of  the  surrounding
arenchyma  and  classiﬁed  as  non-enhancement,  hypo-
nhancement,  iso-enhancement  and  hyper-enhancement.35
his  evaluation  is  easy  to  perform  but  it  is  very  operator
ependent.  To  increase  interobserver  agreement  for  CE-EUS
ecent  studies  used  quantiﬁcation  methods  to  obtain  objec-
ive  results,  such  as  uptake  ratio  index36 and  time  intensity
urve  (TIC)  analysis.37,38
First  reports  have  shown  that  solid  pancreatic  lesions
ay  have  3  main  enhancement  patterns:  hypo-,  iso-  and
164  B.  Gonc¸alves  et  al.
Figure  1  Screen  capture  of  video  sequence  of  contrast-enhanced  harmonic  endoscopic  ultrasonography  (left  panel).  The  video
sequence also  included  a  B-mode  standard  EUS  image  of  the  lesion  of  interest  (right  panel).  This  lesion  has  a  hypo-enhancement
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mattern suggestive  of  pancreatic  adenocarcinoma  (this  was  con
yper-enhancement.14--16 Pancreatic  adenocarcinoma  most
ommonly  shows  a  hypo-enhancement  pattern.14,15 Pseu-
otumoral  chronic  pancreatitis  is  usually  iso-enhanced  or
yper-enhanced,38 while  neuroendocrine  tumor  (NET)  is
ommonly  hyper-enhanced.39 Recently,  three  groups  have
rospectively  evaluated  the  performance  of  qualitative
E-EUS  in  characterizing  solid  pancreatic  lesions.39--41 Ade-
ocarcinoma  was  diagnosed  as  a  hypo-enhanced  mass  with
igh  sensitivity  (89--95%)  and  speciﬁcity  (64--89%).  A  hyper-
nhanced  pattern  of  the  mass  on  CE-EUS  was  88--94%
redictive  of  a  lesion  other  than  adenocarcinoma  in  the  two
rst  series,  whereas  a  hyper-enhanced  pattern  diagnosed
euroendocrine  tumor  with  a  sensitivity  and  speciﬁcity  of
9%  and  99%,  respectively,  in  the  last  series.
The  performance  of  quantitative  CE-EUS  in  the  diagnosis
f  pancreatic  adenocarcinoma  has  been  evaluated  in  three
tudies.36--38 Seicean  et  al36 showed  that  the  uptake  ratio
ndex  was  signiﬁcantly  lower  for  pancreatic  adenocarcinoma
han  for  pseudotumoral  chronic  pancreatitis,  with  a  sensitiv-
ty  of  80%  and  a  speciﬁcity  of  91%.  Using  time  intensity  curves
TICs),  Matsubara  et  al37 revealed  that  the  echo-intensity
eduction  rate  from  its  peak  at  1  min  was  greatest  in  pan-
reatic  adenocarcinoma,  followed  by  chronic  pancreatitis,
utoimmune  pancreatitis  and  NET.  CE-EUS  in  combination
ith  TIC  increased  the  sensitivity,  speciﬁcity  and  accuracy  to
6%,  93%,  and  95%,  respectively.  Gheonea  et  al38 conﬁrmed
tatistically  signiﬁcant  differences  in  TIC  values  when  com-
aring  pseudotumoral  chronic  pancreatitis  and  pancreatic
denocarcinoma.
In  a  recent  meta-analysis,42 the  pooled  sensitivity  of
E-EUS  for  the  differential  diagnosis  of  pancreatic  adeno-
arcinoma  was  94%  and  the  speciﬁcity  was  89%.  The  AUROC
as  0.973.  Besides  characterization  of  pancreatic  lesionsn  general,  CE-EUS  may  be  particularly  useful  for  detection
nd  characterization  of  small  (<2  cm)39 or  solid  pancreatic
esions  that  are  associated  with  biliary  stents  or  chronic
ancreatitis.41 CE-EUS  has  also  been  shown  to  be  useful
s
t
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ud  by  EUS-FNA).
or  preoperative  localization  of  NET’s,43 differentiation  of
ural  nodules  in  intraductal  papillary  mucinous  neoplasms
nd  detection  of  malignant  transformations44,45 and  for  pre-
icting  and  monitoring  response  of  pancreatic  cancer  to
hemotherapy.46,47
CE-EUS  has  however  some  limitations.  As  the  component
hell  and  excipients  of  the  UCAs  are  derived  from  macro-
olecular  substances,  there  is  a  risk  of  allergic  reactions.  In
ddition,  UCAs  should  not  be  used  in  patients  with  unstable
schemic  heart  disease.48 The  differential  diagnosis  between
ancreatic  adenocarcinoma  and  pseudotumoral  chronic  pan-
reatitis  may  also  be  particularly  challenging  since,  similarly
o  pancreatic  adenocarcinoma,  pseudotumoral  chronic  pan-
reatitis  may  show  hypo-enhancement  at  CE-EUS  depending
n  the  degree  of  inﬂammation  and  ﬁbrosis.35,39--41
.2.  EUS-elastography  (EUS-E)
he  basis  for  elastography  is  the  fact  that  many  differ-
nt  pathologic  processes,  including  inﬂammation,  ﬁbrosis,
nd  cancer,  induce  alterations  in  tissue  stiffness.  EUS-E
valuates  tissue  stiffness  through  the  application  of  slight
ompression  to  the  targeted  tissue  and  recording  the  result-
ng  tissue  displacement  in  the  examined  ﬁeld.49 The  images
re  obtained  in  real  time,  being  overimposed  as  a  transpar-
nt  color  overlay  on  the  usual  EUS  gray-scale  images  (Fig.  2).
lasticity  is  depicted  using  a  color  map,  wherein  hard  tissue
s  shown  in  dark  blue,  medium  hard  tissue  in  cyan,  tissue
ith  intermediate  hardness  in  green,  medium  soft  tissue  in
ellow  and  soft  tissue  in  red.  The  region  of  interest  (ROI)
or  the  elastographic  evaluation  is  manually  selected.  Opti-
ally,  the  ROI  includes  the  whole  target  lesion,  as  well  asome  surrounding  tissues  for  reference.  The  ﬁrst  genera-
ion  of  EUS  elastography  allowed  only  qualitative  evaluation.
oday,  the  second  generation  also  allows  quantitative  eval-
ation  of  tissue  stiffness.50
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Figure  2  Screen  capture  of  video  sequence  of  endoscopic  ultrasound  elastography  (left  panel).  The  video  sequence  also  included
a B-mode  standard  EUS  image  of  the  lesion  of  interest  (right  panel).  This  lesion  has  a  heterogeneous  blue-predominant  pattern
suggestive of  pancreatic  adenocarcinoma  (this  was  conﬁrmed  by  EUS-FNA).
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iQualitative  elastography  involves  the  evaluation  of  the
pattern  of  the  elastogram  such  as  the  major  color  tone  and
the  heterogeneity  of  the  color  tones.51 This  method  is  highly
operator  dependent  and  so  different  image  analysis  tech-
niques  were  developed  to  evaluate  the  characteristics  of  a
lesion  in  a  quantitative  manner.  These  include  the  hue  his-
togram  and  the  strain  ratio.  The  hue  histogram  is  a  graphical
representation  of  the  color  distribution  (hues)  in  a  selected
image  ﬁeld.  Hue  histograms  are  based  on  the  qualitative  EUS
elastography  data  for  a  manually  selected  ROI  within  the
standard  elastography  image.52 The  histogram  analysis  can
even  be  taken  one  step  further,  by  training  artiﬁcial  neu-
ral  networks  to  make  the  distinction  between  benign  and
malignant  histograms.52 Strain  ratio  compares  the  average
strain  in  two  different  areas  of  the  ROI.50 Using  the  standard
qualitative  EUS  elastographic  image,  the  operator  selects
two  no  overlapping  areas  inside  the  ROI:  The  lesion  (area  A)
and  the  reference  zone  (area  B;  usually  adipose  or  connec-
tive  tissues  that  have  little  to  no  inter-individual  hardness
variance).  The  B/A  quotient  obtained  represents  the  SR.53
First  qualitative  EUS-E  experiences  were  published  by
Giovannini  et  al  who  implemented  a  qualitative  scoring
system  based  on  the  lesions  color  pattern;  hard,  mostly
blue  lesions  were  classiﬁed  as  malignant.54 Sensitivity  and
speciﬁcity  were,  respectively,  100%  and  67%.  A  reﬁning  of
this  system  created  a  ﬁve-score  classiﬁcation  that  achieved
overall  accuracy  of  89.2%  in  a  multicenter  study,55 with  sen-
sitivity  and  positive  predictive  value  (PPV)  being  over  90%.
Iglesias-Garcia  et  al  have  described  four  similar  patterns:
homogeneous  green  for  normal  pancreas;  heterogeneous,
green-predominant  for  inﬂammatory  pancreatic  masses;
heterogeneous,  blue-predominant  for  pancreatic  malignant
tumors;  and  homogeneous  blue  for  pancreatic  neuroen-
docrine  malignant  lesions.  This  classiﬁcation  brought  an
almost  5%  increase  of  accuracy,  up  to  94.0%.56 More  recently,
d
o
w
ptudies  have  been  published  using  quantitative  EUS  elastog-
aphy.  Saftoiu  et  al  used  hue  histograms  in  two  different
tudies27,51 obtaining  good  sensitivities  (93.4%  and  91.4%)
ut  varying  speciﬁcities  (66.0%  and  87.9%).  Overall  accura-
ies  in  these  studies  were  only  slightly  lower  than  the  ones
btained  by  Itokawa  et  al57 and  Iglesias-Garcia  et  al53 using
 strain  ratio  protocol.  The  same  strain  ratio  protocol  was
lso  used  by  Dawwas  et  al  in  a large  single-center  prospec-
ive  study58 achieving  a  sensitivity  of  100.0%,  poor  speciﬁcity
f  16.7%  and  an  overall  accuracy  of  86.5%.
The  subject  of  elastographic  differential  diagnosis  was
lso  covered  in  a  recent  meta-analysis.59 In  this  meta-
nalysis  the  pooled  sensitivity,  speciﬁcity,  and  diagnostic
dds  ratio  of  EUS-E  distinguishing  benign  from  malignant
olid  pancreatic  masses  were  95%,  67%  and  42.28,  respec-
ively.  The  AUROC  was  0.9046.
EUS-E  has  however  some  intrinsic  limitations.53,56 Recent
tudies  have  indicated  that  elastography  for  the  diagnosis  of
nﬂammatory  masses  may  be  particularly  difﬁcult  in  patients
ith  advanced  chronic  pancreatitis  since  the  inﬂamma-
ory  mass  may  produce  a  heterogeneous  blue-predominant
attern,  which  is  similar  to  that  observed  in  pancreatic
alignancies.27 Color  pattern  as  a  qualitative  pattern  anal-
sis  provides  a  subjective  determination  that  is  associated
ith  intraobserver  and  interobserver  variability.60 The  quan-
itative  method  of  hue  histogram  and  strain  ratio  might  be
elpful,  but  there  were  still  some  limitations.  Hue  histogram
nd  strain  ratio  could  be  hampered  by  the  selection  of  the
mages.61,62 Although  dynamic  analysis  of  EUS-E  for  hue  his-
ogram  could  eliminate  the  selection  bias,  artifacts  may  be
nduced  by  the  surrounding  presence  of  very  low  or  hard
ensity  and  stiffness  tissues.61 There  is  also  a  wide  range
f  cut-offs  for  strain  ratio  within  different  studies,  all  of
hich  were  determined  after  data  collection,  and  no  study
rospectively  determined  them.38
1 B.  Gonc¸alves  et  al.
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Table  1  TNM  staging  system  for  pancreatic
adenocarcinoma.
Primary  tumor  (T)
TX:  Primary  tumor  cannot  be  assessed
T0: No  evidence  of  primary  tumor
Tis:  Carcinoma  in  situ
T1: Tumor  limited  to  the  pancreas,  ≤2  cm  in  greatest
dimension
T2: Tumor  limited  to  the  pancreas,  >2  cm  in  greatest
dimension
T3:  Tumor  extends  beyond  the  pancreas  but  without
involvement  of  the  celiac  axis  or  the  superior  mesenteric
artery
T4: Tumor  involves  the  celiac  axis  or  the  superior
mesenteric  artery  (unresectable  primary  tumor)
Regional  lymph  nodes  (N)
NX:  Regional  lymph  nodes  cannot  be  assessed
N0: No  regional  lymph  node  metastasis
N1: Regional  lymph  node  metastasis
Distant  metastases  (M)
M0:  No  distant  metastasis
M1:  Distant  metastasis
Stage  0--Tis,  N0,  M0
Stage  IA--T1,  N0,  M0
Stage  IB--T2,  N0,  M0
Stage  IIA--T3,  N0,  M0
Stage  IIB--T1,  N1,  M0  or  T2,  N1,  M0  or  T3,  N1,  M0
Stage III--T4,  any  N,  M0
Stage  IV--any  T,  any  N,  M1
(AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
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. Point of view
lthough  CE-EUS  and  EUS-E  will  hardly  replace  EUS-FNA,
hey  can  be  efﬁcient  complementary  tools  to  differentiate
olid  pancreatic  lesions,  mainly  by  reducing  the  number  of
alse  negatives  of  EUS-FNA.  Given  the  higher  sensitivity  of
E-EUS  and  EUS-E  a  negative  cytology  by  EUS-FNA  should  not
e  considered  as  a  benign  lesion  when  CE-EUS  and/or  EUS-E
re  suggestive  of  pancreatic  adenocarcinoma.  In  these  cases
urther  cytological  samples  or  surgery  should  be  considered
nstead  of  follow-up.  This  has  been  evaluated  in  two  studies.
apoleon  et  al40 observed  that  4  out  of  5  adenocarcinomas
ith  false-negative  EUS-FNA  ﬁndings  were  hypo-enhanced
t  CE-EUS.  Additionally,  CE-EUS  revealed  that  all  ductal
arcinomas  with  false-negative  EUS-FNA  results  had  hypo-
nhancement  in  the  study  by  Kitano  et  al.39 In  addition,
E-EUS  and  EUS-E  could  guide  FNA  to  choose  an  optimal
uncture  site  to  improve  the  diagnostic  accuracy.  This  has
een  evaluated  by  Kitano  et  al63 who  performed  FNA  guided
y  CE-EUS  on  39  patients  with  pancreatic  tumors.  No  viable
ells  were  found  in  areas  with  no  enhancement,  whereas
dequate  samples  were  obtained  from  80%  of  sites  with  a
eterogeneous  vascular  pattern  and  in  all  cases  from  areas
ith  a  homogeneous  pattern.
Based  on  the  available  data,  we  believe  CE-EUS  and  EUS-
 are  ready  for  use  in  clinical  practice  as  complementary
ools  for  EUS-FNA.  Nonetheless  these  techniques  should  be
sed  only  by  endosonographers  who  have  received  proper
raining,  ideally  in  reference  centers.
. EUS in the staging of pancreatic cancer
reatment  of  pancreatic  cancer  is  an  evolving  ﬁeld  and
n  accurate  staging  becomes  increasingly  important.  The
taging  of  pancreatic  cancer  is  based  on  the  tumor-node-
etastasis  (TNM)  system  (Table  1).  From  a  clinical  point  of
iew,  the  goal  of  preoperative  staging  is  to  identify  3  dif-
erent  stages  of  pancreatic  cancer  and  its  treatment:  (1)
esectable  tumor  that  should  be  referred  directly  for  cura-
ive  surgery;  (2)  locally  advanced/borderline  tumor  that
an  be  considerer  to  neoadjuvant  chemoradiation  and  (3)
etastatic/unresectable  tumor  that  should  be  directed  to
alliative  chemotherapy.  Current  practice  in  expert  centers
as  evolved  to  surgical  excision  of  pancreatic  adenocarci-
oma  regardless  of  extension  to  adjacent  structures  (such
s  transverse  colon,  stomach,  spleen,  adrenal  gland  and  kid-
ey),  since  these  structures  can  be  resected  along  with  the
rimary  tumor.  On  the  other  hand,  the  resectability  status
epends  greatly  on  vascular  invasion,  and  its  criteria  were
ecently  reviewed  (Table  2).64
.1.  Overall  performance
ultiple  imaging  modalities  are  available  for  staging  pancre-
tic  cancer,  and  there  is  no  evidence-based  consensus  on  the
ptimal  preoperative  imaging  assessment  of  these  patients.
everal  studies  have  been  published  assessing  the  accuracy
f  EUS  for  staging  pancreatic  cancer,  and  two  recent  meta-
nalyses  evaluated  the  performance  characteristics  of  EUS
n  this  setting.  In  the  ﬁrst  one,  including  29  studies  with
 total  of  1330  patients,  the  estimated  pooled  sensitivity
h
c
a
vp. 241).
nd  speciﬁcity  was  69%  and  81%  for  N  staging;  85%  and  91%
or  vascular  invasion  and  90%  and  86%  for  resectability.65
n  the  second  meta-analysis,  including  20  studies  with  726
atients,  the  estimated  pooled  sensitivity,  speciﬁcity  and
UROC  were  72%,  90%  and  0.90  for  early  and  intermediate
isease  (T1  and  T2);  90%,  72%  and  0.90  for  advanced  disease
T3  and  T4);  62%,  74%  and  0.79  for  N  staging  and  87%,  92%
nd  0.94  for  vascular  invasion.66 It  seems  that  EUS  has  lower
ccuracy,  mostly  less  sensitivity,  in  staging  the  N  status.  In
his  sense,  the  use  of  EUS-FNA  in  addition  to  diagnostic  EUS
as  the  potential  to  increase  the  accuracy  of  nodal  staging
p  to  85%.67,68 At  present,  regarding  EUS  technologies,  there
s  not  enough  evidence  to  show  a  difference  in  the  accuracy
etween  linear  and  radial  probes.65,69 Keeping  in  mind  the
ossible  need  to  perform  EUS-FNA  as  a diagnostic  and  staging
djuvant,  the  use  of  a  linear  probe  could  be  more  suitable.
.2.  Resectability  and  vascular  invasion
s  previously  stated,  the  evaluation  of  vascular  invasion  is
eterminant  for  assessing  tumor  resectability.  Several  EUS
riteria  have  been  proposed  to  predict  vascular  invasion,
owever  the  most  reliable  are70:  (1)  peripancreatic  venous
ollaterals  in  an  area  of  a  mass  that  obliterates  the  normal
natomic  location  of  a  major  vessel;  (2)  tumor  within  the
essel  lumen  and  (3)  abnormal  vessel  contour  or  irregular
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Table  2  Criteria  for  pancreatic  adenocarcinoma  staging.
Stage  Arterial  Venous
Resectable  Clear  fat  planes  around  CA,  SMA,  and  HA  No  SMV/portal  vein  distortion
Borderline  resectable  Gastroduodenal  artery  encasement  up  to  the
hepatic  artery  with  either  short  segment
encasement  or  direct  abutment  of  the  hepatic
artery  without  extension  to  the  CA.  Tumor
abutment  of  the  SMA  not  to  exceed  greater
than 180◦ of  the  circumference  of  the  vessel
wall
Venous  involvement  of  the  SMV  or  portal  vein
with distortion  or  narrowing  of  the  vein  or
occlusion  of  the  vein  with  suitable  vessel
proximal  and  distal,  allowing  for  safe  resection
and replacement
Any  IVC  abutment
Unresectable* Aortic  invasion  or  encasement.  Based  on  tumor
location:
- Pancreatic  head----More  than  180◦ SMA
encasement,  any  CA  abutment
- Pancreatic  body/tail----SMA  or  CA  encasement
greater  than  180◦
Unreconstructible  SMV/portal  vein  occlusion
CA- celiac axis; HA- hepatic artery; IVC- inferior vena cava; SMA/SMV- superior mesenteric artery/vein.
* The presence of distant metastasis, including metastases to lymph nodes beyond the ﬁeld of resection, renders the patient unre-
sectable irrespective of the type of vascular involvement.
(Al-Hawary et al Gastroenterology 2014; 146: 291--304, NCCN practice guidelines for Pancreatic Adenocarcinoma, version 1.2015;
http://www.nccn.org).
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techniques  and  EUS  are  not  mutually  exclusive  and  shouldwall  with  loss  of  the  vessel-parenchymal  sonographic  inter-
face.  Puli  et  al69 published  a  meta-analysis  on  the  diagnostic
accuracy  of  EUS  for  vascular  invasion,  in  which  the  pooled
sensibility  was  73%  and  the  speciﬁcity  90%.  The  accuracy  of
EUS  also  varies  with  the  vessel  being  examined.  As  a  gen-
eral  rule,  EUS  has  a  better  performance  for  venous  invasion
(80--91%)  compared  to  arterial  invasion  (17--67%).65 The  bet-
ter  results  are  seen  for  portal  vein  and  conﬂuence,  where
the  sensitivity  increases  up  to  100%,  and  for  the  splenic
artery  and  vein.  In  contrast,  the  sensitivity  of  EUS  decreases
for  the  evaluation  of  the  celiac  axis  and  the  superior  mesen-
teric  artery  and  vein.71
6.3.  Comparison  of  EUS  with  computed
tomography  (CT)
In  a  systematic  review,  Dewitt  et  al72 analyzed  eleven  well-
designed  studies  comparing  EUS  and  CT  for  preoperative
staging  of  pancreatic  cancer.  Regarding  the  T  stage  accu-
racy,  4 of  5  studies  concluded  that  EUS  was  superior  to
CT  (63--85%  vs.  25--73%).  EUS  was  also  superior  to  CT  in  5
of  8  studies  that  assessed  N  staging  accuracy  (44--75%  vs.
25--63%).  Among  the  4  studies  that  assessed  resectability,  2
showed  no  difference  between  EUS  and  CT,  and  1  favored
each  modality.  For  vascular  invasion  EUS  was  superior  to  CT
in  6  of  8  studies  (68--100%  vs.  41--83%).  The  previously  men-
tioned  meta-analysis  by  Nawaz  et  al65 included  12  studies
on  the  same  subject.  CT  showed  lower  sensitivity  than  EUS
for  N  staging  (24%  vs.  58%)  and  vascular  invasion  (58%  vs.
86%);  however,  the  speciﬁcities  for  N  staging  (88%  vs.  85%)
and  vascular  invasion  (95%  vs.  93%)  were  comparable.  The
sensitivity  and  speciﬁcity  of  CT  in  determining  resectability
(90%  and  69%)  was  similar  to  that  of  EUS  (87%  and  89%).
Only  a  few  studies  comparing  EUS  with  multidetector  row
CT  (MDR-CT)  for  staging  pancreatic  cancer  are  available.  In
b
B
s
r report  of  80  patients,  EUS  was  superior  to  MDR-CT  for  T
taging  accuracy  (67%  vs.  41%)  but  equivalent  for  N  stag-
ng  accuracy  (44%  vs.  47%),  detection  of  resectable  tumors
88%  vs.  92%)  and  unresectable  tumors  (68%  vs.  64%).73 In  a
ore  recent  study,  the  sensitivity,  speciﬁcity  and  area  under
he  curve  for  EUS  vascular  invasion  were  61%,  90%  and  0.80
ompared  to  56%,  93%  and  0.74  for  MDR-CT.74
.4.  Comparison  of  EUS  with  magnetic  resonance
maging (MRI)
ikewise  with  MDR-CT,  there  are  few  studies  comparing  EUS
nd  MRI.  Soriano  et  al23 showed  that  for  N  staging  MRI
ad  a  lower  sensitivity  (15%)  but  higher  speciﬁcity  (93%)
hen  compared  with  EUS  (36%  and  87%,  respectively)  and
T  (37%  and  79%,  respectively).  Regarding  vascular  inva-
ion  MRI  had  sensitivity  of  59%  and  speciﬁcity  of  84%  in
omparison  to  EUS  (42%  and  97%,  respectively)  and  CT
67%  and  94%,  respectively).  In  a recent  prospective  study
he  agreement  between  EUS  and  MRI  in  patients  staging
as  74%,  with  a  fair  correlation  between  both  techniques
kappa  0.42).75
When  comparing  EUS  with  other  imaging  techniques,  it
s  important  to  stress  that  EUS  is  a real-time  operator-
ependent  technique  with  a  slow  learning  curve  that  can
ffect  its  performance.  However  there  are  no  data  evaluat-
ng  the  impact  of  these  variables  in  the  staging  of  pancreatic
ancer  and  it  would  be  interesting  to  conduct  a  study  on
his  speciﬁc  subject.  In  conclusion,  cross-sectional  imaginge  considered  complementary  for  staging  pancreatic  cancer.
oth  EUS  and  CT/MDR-CT  appear  to  be  equivalent  for  nodal
taging,  overall  vascular  invasion,  and  assessment  of  tumor
esectability  (Table  3).
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. Conclusion
US  is  crucial  for  an  accurate  preoperative  evaluation  of
ancreatic  cancer  which  is  essential  to  choose  the  correct
anagement  strategy.23,24 The  possibility  to  obtain  sam-
les,  from  suspicious  lesions  or  lymph  nodes,  by  means
f  EUS-FNA,  makes  this  procedure  an  ideal  diagnosing  and
taging  modality  for  pancreatic  cancer.  EUS-FNA  allows  the
iagnosis  of  solid  pancreatic  lesions  other  than  ductal  ade-
ocarcinoma,  staging  of  suspected  or  proven  pancreatic
ancer,  and  cytological/histological  proof  of  unresectable
ancreatic  cancer.23,24 Nonetheless,  EUS-FNA  may  provide
alse-negative  results  for  malignancy,  especially  for  the
atients  with  underlying  chronic  pancreatitis.2,27 The  diag-
ostic  yield  of  EUS-FNA  may  be  improved  by  ROSE,6 correct
hoice  of  the  needle,13 the  number  of  passes15 and  repeti-
ion  of  the  procedure.  Another  option  to  raise  the  diagnostic
ield  of  EUS-FNA  is  the  addition  of  CE-EUS  and/or  EUS-E.
iven  the  higher  sensitivity  of  CE-EUS  and  EUS-E,  in  cases  of
egative  cytology  by  EUS-FNA  but  in  which  CE-EUS  and/or
US-E  is/are  suggestive  of  pancreatic  adenocarcinoma,  fur-
her  cytological  samples  or  surgery  should  be  considered
nstead  of  follow-up.39,40 In  addition,  CE-EUS  and  EUS-E
ould  guide  FNA  to  choose  an  optimal  puncture  site  to
mprove  the  diagnostic  accuracy63.
For  staging  and  assessment  of  resectability  of  pancreatic
ancer,  EUS  is  applied  supplementary  to  CT.76 While  the  sec-
nd  should  be  the  ﬁrst  choice  in  patients  with  suspected
ancreatic  cancer,  EUS  may  provide  better  assessment  of
 staging  and  certain  types  of  vascular  invasion.77,78 Thus
US  plays  a  major  role  to  further  evaluate  patients  with
on-metastatic  disease  that  appears  resectable  on  initial
maging.77,78
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